We are identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing the excess labile iron that contributes to the pathologic process. Our clinical development program is currently focused on MSA, a rare Parkinsonian disorder with no approved treatments that address the underlying pathology of the disease.
Status note Lead product candidate; company developing disease-modifying therapies for MSA and other Parkinsonian disorders. Successful End-of-Phase 2 meeting with FDA in June 2026 aligned key elements of registrational Phase 3 program in MSA.
Per-asset detail extracted from the 20-F filed 2026-08-28. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.